KCNK3 protein E182Q mutant mouse used as pulmonary arterial hypertension model as well as preparation method and application of KCNK3 protein E182Q mutant mouse
Through CRISPR/Cas9 gene editing technology, the E182Q mutation of KCNK3 protein was introduced into mice, and a pulmonary hypertension model was constructed, which solved the problem that the existing model could not fully reflect the human pulmonary hypertension phenotype, and achieved spontaneous generation of pulmonary hypertension phenotype. Provides a new platform for the research and drug development of pulmonary hypertension.
Patent Information
- Application Number
- CN202310527961.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-11
- Publication Date
- 2024-11-12
AI Technical Summary
The existing KCNK3 mutant animal models cannot fully reflect the phenotype of human pulmonary arterial hypertension and cannot be effectively used for pathogenic mechanism research and drug development.
The E182Q mutation of KCNK3 protein was introduced into mice through CRISPR/Cas9 gene editing technology, and a pulmonary arterial hypertension model was constructed, targeted mutations were achieved and mice with spontaneous pulmonary hypertension phenotype were screened.
The pathogenic process of human pulmonary hypertension has been successfully reproduced, providing a new research platform for the study of pathogenic mechanisms and drug development of pulmonary hypertension, and can spontaneously generate pulmonary hypertension phenotypes.
Smart Images

Figure BDA0004223417300000051 
Figure HDA0004223417310000011 
Figure HDA0004223417310000012
Abstract
Description
Technical Field
[0001] The invention belongs to the field of animal genetic engineering, and relates to a KCNK3 protein E182Q mutant mouse used as a pulmonary hypertension model, and a preparation method and application thereof. Background Art
[0002] Pulmonary Arterial Hypertension (PAH) is an extremely serious disease. Although the application of some new drugs and gene therapy, living lung transplantation, atrial septal fistula and other new therapies in recent years has improved the average survival rate of patients for 5 or 10 years, most of the treatment plans only relieve symptoms but cannot change the course of the disease and clinical consequences. One of the important reasons is that the pathogenic mechanism of PAH is not yet fully understood, and the relationship between its pathogenesis and clinical phenotype is not yet clear.
[0003] 70-80% of hereditary pulmonary hypertension has pathogenic gene mutations, while 10-30% of idiopathic pulmonary hypertension is related to pathogenic gene mutations. With the development of genetic engineering technology, the success of gene knock-in mouse preparation has made it possible to reproduce the human pulmonary hypertension gene mutation in mice, which not only helps to understand the relationship between genotype and clinical phenotype and explore the mechanism of these mutation sites leading to disease occurrence, but also provides an animal model for the development of drugs for pulmonary hypertension.
[0004] In recent years, some mutation sites have been discovered and prepared into transgenic mice, which can replicate pathogenic gene mutant mice, which can show pulmonary hypertension phenotypes. However, most mutations rarely show spontaneous phenotypes in animal models. Recently, some rare pathogenic gene mutations have been found in some clinical studies of pulmonary hypertension. Among them, mutations in the potassium ion channel protein KCNK3 can cause pulmonary hypertension, which has attracted attention to the role of ion channel diseases in the occurrence and development of pulmonary hypertension. In 2017, Kitagawa M et al. found that knocking out the KCNK3 mutation in mice did not cause pulmonary hypertension phenotypes. In addition, in 2019, Lambert M et al. published two articles, constructing a 94bp frame deletion mutation at the position of rat exon 1, and found that rats could slightly increase right ventricular systolic pressure at 4 months old, but could not cause right ventricular hypertrophy. When hypoxia was induced, it was found that mutant mice were more likely to cause pulmonary hypertension. The above work suggests that the current KCNK3 mutation animal model cannot fully reflect the phenotype of human pulmonary hypertension. Summary of the invention
[0005] The purpose of the present invention is to provide a KCNK3 protein E182Q mutant mouse used as a pulmonary hypertension model and a preparation method and application thereof.
[0006] The present invention provides a method for preparing a mouse model of pulmonary hypertension, comprising the following steps:
[0007] A chromosome of a wild-type mouse is subjected to targeted mutation to obtain a mutant mouse (heterozygous mutant mouse);
[0008] The targeted mutation refers to: mutating the codon encoding the 182nd amino acid residue of the KCNK3 protein in the mouse genomic DNA from a codon encoding glutamic acid (E) to a codon encoding glutamine (Q).
[0009] The targeted mutation refers to: mutating the codon encoding the 182nd amino acid residue of KCNK3 protein in the mouse genomic DNA from gag to CAG.
[0010] The directed mutation refers to replacing the DNA segment shown in Sequence 5 of the sequence listing in the genomic DNA with the DNA segment shown in Sequence 4 of the sequence listing.
[0011] The KCNK3 protein is specifically shown in Sequence 7 of the sequence listing.
[0012] The present invention also provides a method for preparing a pulmonary hypertension mouse model, comprising the following steps:
[0013] The RNP complex is introduced into wild-type mouse fertilized eggs, which are then transferred into the uterus of surrogate mice. The offspring produced by the surrogate mice are then screened for mice with a targeted mutation on one chromosome;
[0014] The RNP complex includes crRNA, tracrRNA, donor oligo and Cas9 protein;
[0015] The target sequence of crRNA is: CCTTCTCCTACTACGAGCGC TGG;
[0016] The donor oligo is shown as sequence 3 in the sequence listing;
[0017] The directed mutation refers to replacing the DNA segment shown in Sequence 5 of the sequence listing in the genomic DNA with the DNA segment shown in Sequence 4 of the sequence listing.
[0018] The present invention also provides a method for preparing a pulmonary hypertension mouse model, comprising the following steps:
[0019] A pair of homologous chromosomes of wild-type mice are subjected to targeted mutation to obtain mutant mice (homozygous mutant mice);
[0020] The targeted mutation refers to: mutating the codon encoding the 182nd amino acid residue of the KCNK3 protein in the mouse genomic DNA from a codon encoding glutamic acid (E) to a codon encoding glutamine (Q).
[0021] The targeted mutation refers to: mutating the codon encoding the 182nd amino acid residue of KCNK3 protein in the mouse genomic DNA from gag to CAG.
[0022] The directed mutation refers to replacing the DNA segment shown in Sequence 5 of the sequence listing in the genomic DNA with the DNA segment shown in Sequence 4 of the sequence listing.
[0023] The KCNK3 protein is specifically shown in Sequence 7 of the sequence listing.
[0024] The present invention also provides a method for preparing a pulmonary hypertension mouse model, comprising the following steps:
[0025] The RNP complex is introduced into wild-type mouse fertilized eggs, which are then transferred into the uterus of surrogate mice. The offspring mice produced by the surrogate mice are then screened for mice with targeted mutations in both homologous chromosomes.
[0026] The RNP complex includes crRNA, tracrRNA, donor oligo and Cas9 protein;
[0027] The target sequence of crRNA is: CCTTCTCCTACTACGAGCGC TGG;
[0028] The donor oligo is shown as sequence 3 in the sequence listing;
[0029] The directed mutation refers to replacing the DNA segment shown in Sequence 5 of the sequence listing in the genomic DNA with the DNA segment shown in Sequence 4 of the sequence listing.
[0030] Specifically, any of the above methods further comprises the following steps: breeding the mutant mice continuously for one or more generations, and obtaining mutant mice by screening the offspring.
[0031] The breeding may be: mating male mutant mice and female mutant mice to obtain offspring.
[0032] The breeding may be: mating mutant mice with wild-type mice to obtain offspring.
[0033] The multiple generations may be 2 generations, 3 generations, 4 generations, 5 generations, etc.
[0034] Specifically, any of the above methods further comprises the following step: culturing the mutant mice to 4 months of age, i.e., a pulmonary hypertension mouse model.
[0035] The present invention also protects the use of crRNA, tracrRNA and donor oligo in preparing a kit; the kit is used to prepare a pulmonary hypertension mouse model;
[0036] The target sequence of crRNA is: CCTTCTCCTACTACGAGCGC TGG;
[0037] The donor oligo is shown as Sequence 3 in the Sequence Listing.
[0038] Specifically, the ratio of crRNA, tracrRNA and donor oligo can be: 20pmol crRNA: 20pmoltracrRNA: 1pmol donor oligo.
[0039] The present invention also protects the use of crRNA, tracrRNA, donor oligo and Cas9 protein in preparing a kit; the kit is used to prepare a pulmonary hypertension mouse model;
[0040] The target sequence of crRNA is: CCTTCTCCTACTACGAGCGC TGG;
[0041] The donor oligo is shown as Sequence 3 in the Sequence Listing.
[0042] Specifically, the ratio of crRNA, tracrRNA, donor oligo and Cas9 protein can be: 20pmol crRNA: 20pmol tracrRNA: 1pmol donor oligo: 300ng Cas9 protein.
[0043] The present invention also protects a kit, comprising crRNA, tracrRNA and donor oligo; the kit is used to prepare a pulmonary hypertension mouse model;
[0044] The target sequence of crRNA is: CCTTCTCCTACTACGAGCGC TGG;
[0045] The donor oligo is shown as Sequence 3 in the Sequence Listing.
[0046] Specifically, the ratio of crRNA, tracrRNA and donor oligo can be: 20pmol crRNA: 20pmoltracrRNA: 1pmol donor oligo.
[0047] The kit also includes a Cas9 protein.
[0048] Specifically, the ratio of crRNA, tracrRNA, donor oligo and Cas9 protein can be: 20pmol crRNA: 20pmol tracrRNA: 1pmol donor oligo: 300ng Cas9 protein.
[0049] Specifically, any of the above crRNAs is shown in Sequence 1 of the sequence listing.
[0050] Specifically, any of the above tracrRNAs is shown in Sequence 2 of the sequence listing.
[0051] Cas9 protein, also known as Cas9 nuclease.
[0052] Specifically, any of the above-mentioned wild-type mice may be C57 mice.
[0053] Specifically, any of the above-mentioned wild-type mice may be C57BL / 6J mice.
[0054] Specifically, any of the above pulmonary hypertension mouse models has the following phenotypes: compared with wild-type mice, right ventricular systolic pressure is increased and / or right ventricular hypertrophy index is increased and / or the percentage of pulmonary artery media thickness is increased.
[0055] Specifically, any of the above pulmonary hypertension mouse models has the following phenotypes: right ventricular systolic pressure is greater than 20 mmHg and / or right ventricular hypertrophy index is greater than 33% and / or pulmonary artery media thickness percentage is greater than 55%.
[0056] Specifically, any of the above pulmonary hypertension mouse models has the following phenotypes: right ventricular systolic pressure is greater than 21 mmHg and / or right ventricular hypertrophy index is greater than 35% and / or pulmonary artery media thickness percentage is greater than 58%.
[0057] The present invention also protects the use of the pulmonary hypertension mouse model prepared by any of the above methods, which is as follows (a) or (b) or (c):
[0058] (a) To study the pathogenesis of pulmonary hypertension;
[0059] (b) Development of drugs for pulmonary arterial hypertension;
[0060] (c) Screening of drugs for pulmonary hypertension.
[0061] The present invention adopts CRISPR / Cas9 gene editing technology to construct a pulmonary hypertension model, which is simple, fast and has a high success rate. The pulmonary hypertension mouse model prepared in the present invention can spontaneously produce a pulmonary hypertension phenotype, successfully reproduces the occurrence and development process of human pulmonary hypertension, and provides a new research platform for the study of the pathogenic mechanism of pulmonary hypertension and drug development.
[0062] The inventors of the present invention discovered a new mutation of the KCNK3 protein, namely E182Q, from patients with pulmonary hypertension. Furthermore, the inventors of the present invention used CRISPR / Cas9 gene editing technology and donor DNA to perform targeted mutations on the KCNK3 gene in the mouse genome, and obtained F0 generation heterozygous mutant mice. Furthermore, the inventors of the present invention obtained multiple generations of heterozygous mutant mice by hybridizing with wild-type mice. Heterozygous mutant mice can spontaneously produce a pulmonary hypertension phenotype, and thus can be used as an animal model of pulmonary hypertension for mechanism research and drug development of pulmonary hypertension. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] Figure 1 This is the relevant sequencing comparison between the patients and healthy subjects in Example 1.
[0064] Figure 2 This is a schematic diagram of the target shooting principle in Example 2.
[0065] Figure 3 This is an exemplary electropherogram in Example 2.
[0066] Figure 4 This is an exemplary sequencing result in Example 2.
[0067] Figure 5 These are the statistical results of RVSP and RV / LV+S in Example 3.
[0068] Figure 6 Exemplary photographs of stained pathological sections in Example 3 and statistical results of the percentage of pulmonary artery media thickness. DETAILED DESCRIPTION
[0069] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0070] The experimental methods in the following embodiments, unless otherwise specified, are all conventional methods, and are carried out in accordance with the techniques or conditions described in the literature in this field or in accordance with the product instructions. The materials, reagents, etc. used in the following embodiments, unless otherwise specified, can be obtained from commercial sources. Unless otherwise specified, the quantitative tests in the following embodiments are all repeated three times, and the results are averaged. The animal breeding and reproduction in the embodiments are all carried out in an SPF (specific pathogen free) level experimental animal center. The wild-type mice used in the embodiments are all c57bl / 6j mice (expressed as WT). C57bl / 6j mice: Saiye Biotechnology Co., Ltd., item number C001089.
[0071] Example 1. Discovery of the E182Q mutation and transformation into mice
[0072] The inventors discovered a new KCNK3 mutation in patients with pulmonary hypertension. The mutation is located at position 182 of the KCNK3 protein and is in the form of E182Q, hence the name E182Q mutation. Figure 1 .
[0073] The mouse KCNK3 gene is located on chromosome 5. The E182Q mutation found in the patient was converted to a mutation targeting the mouse KCNK3 gene, namely the g544c mutation. The g544c mutation is located in exon 2 of the KCNK3 gene in the mouse genomic DNA, corresponding to position 544 in the KCNK3 gene coding frame in the mouse cDNA.
[0074] The KCNK3 gene in the mouse cDNA (from the start codon to the stop codon) is shown in Sequence 6 of the sequence listing, encoding the KCNK3 protein shown in Sequence 7 of the sequence listing. The nucleotides of the second exon and its surrounding region in the KCNK3 gene in the mouse genomic DNA are shown in Sequence 8 of the sequence listing.
[0075] The genotype of the wild-type mouse g544c mutation site is homozygous gg.
[0076] Example 2: Construction of KCNK3 protein E182Q mutant mice using CRISPR / Cas9 gene editing technology 1. Preparation of related nucleic acid molecules
[0077] 1. Perform sequence analysis and preliminary experiments to screen and obtain target sequences.
[0078] Target sequence: CCTTCTCCTACTACGAGCGCTGG.
[0079] 2. Preparation of crRNA and tracrRNA
[0080] crRNA is a single-stranded RNA molecule (sequence 1 in the sequence listing), and the nucleic acid sequence is as follows (5'→3' direction): CCUUCUCCUACUACGAGCGCGUUUUAGAGCUAUGCUGUUUUG.
[0081] The tracrRNA is a single-stranded RNA molecule (sequence 2 in the sequence listing), and the nucleic acid sequence is as follows (5'→3' direction): AAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU.
[0082] 3. Preparation of donor oligo
[0083] Donor oligo is a double-stranded DNA molecule (sequence 3 in the sequence list), and the nucleotide sequence is as follows (5'→3' direction):
[0084]
[0085] The straight underlined codons are used to introduce the target amino acid mutations; the wavy underlined codons are synonymous mutation codons to avoid being recognized and cut by the crRNA / tracrRNA / Cas9 complex.
[0086] See the schematic diagram of the target shooting principle Figure 2 .
[0087] 2. Preparation of RNP Complex
[0088] Mix 0.8 μl of 25 pmol / μl crRNA / tracrRNA solution and 1 μl of 300 ng / μl Cas9 nuclease solution and incubate at 25°C for 10 min; then, add 16.4 μl of RNase-free water and 1 μl of 1 pmol / μl donor oligo solution to form the RNP complex.
[0089] The functional components provided by the 25 pmol / μl crRNA / tracrRNA solution are the crRNA prepared in step 1 and the tracrRNA prepared in step 1, wherein the concentrations of the crRNA and the tracrRNA are both 25 pmol / μl.
[0090] The functional component provided by the 300ng / μl Cas9 nuclease solution is Cas9 nuclease, wherein the concentration of Cas9 nuclease is 300ng / μl. Cas9 nuclease: NEB, catalog number M0386M.
[0091] The functional component provided by the 1pmol / μl donor oligo solution is the donor oligo prepared in step 1, wherein the concentration of the donor oligo is 1pmol / μl.
[0092] 3. Construction of KCNK3 protein E182Q mutant mice
[0093] The experimental method was based on the Mouse Embryo Experiment Manual.
[0094] 1. Superovulation in mice
[0095] Four 10-week-old male wild-type mice and 12 6-week-old female wild-type mice were included.
[0096] Female mice were injected with pregnant mare serum gonadotropin (7.5 iu / mouse) at 13:00 on the first day and human chorionic gonadotropin (7.5 iu / mouse) at 13:00 on the third day. At 17:00 on the third day, every 3 female mice were caged together with 1 male mouse. The vaginal plugs of female mice were checked at 8:00-9:00 on the fourth day, and hundreds of 0.5-day-old embryos were flushed out of the oviducts of female mice with plugs.
[0097] 2. Electroporation of fertilized eggs
[0098] Turn on the electroporator, connect the positive and negative electrodes, set the electroporation parameters, and set aside.
[0099] The 0.5-day embryos obtained in step 1 are placed in an acid solution to weaken the zona pellucida for 10-20 seconds; at the same time, the RNP complex prepared in step 2 is added to the electrode dish.
[0100] The weakened embryos were washed three times and transferred to an electrode dish for electroporation; the embryos after electroporation were transferred to M16 culture medium and placed in a 37°C constant temperature 5% CO2 incubator for 0.5-1h, and then transplanted in step 3.
[0101] 3. Perform embryo transplantation and obtain offspring mice
[0102] Prepare pseudo-pregnant female mice: Select fertile female wild-type mice of appropriate age and mate them with male wild-type mice that have been sterilized after vasectomy, stimulate the female mice to undergo a series of pregnancy changes and obtain pseudo-pregnant female mice as surrogate mice.
[0103] The embryos completed in step 2 are transplanted into the oviduct of the surrogate mice on the day of follicle embolism. After the transplantation is completed, the surrogate mice are placed in a clean cage and kept warm until they wake up and then returned to the cage for feeding.
[0104] The surrogate mice gave birth to offspring 19-20 days after the fertilized egg transplantation, which were the F0 generation mice.
[0105] One week after birth, the paws of F0 mice were clipped and numbered.
[0106] F0 mice can be raised independently in separate cages 3 weeks after birth.
[0107] 4. Molecular Characterization of Mice
[0108] In step 3, the tails of the F0 generation mice one week after birth were clipped. The genomic DNA of the tail tissue was extracted, and PCR amplification was performed using a primer pair consisting of F1 and R1, and then the PCR amplification product was recovered and sequenced.
[0109] Wild-type mice were used as controls. Genomic DNA was extracted from tail tissues and PCR amplified using a primer pair consisting of F1 and R1. The PCR amplification products were then recovered and sequenced.
[0110] F1: 5'-ATCTCTACAGGCTATGGTCATG-3';
[0111] R1: 5'-TTCATGGTCATGAATCGCAGC-3'.
[0112] An exemplary electropherogram is shown in Figure 3 . The PCR amplification products of F0 generation mice and wild-type mice are both 476bp. Heterozygous mutant mice are screened according to the sequencing results. Heterozygous mutant mice refer to: a mutant segment on one homologous chromosome (the mutant segment is also called the MT segment, as shown in sequence 4 of the sequence table) and a wild-type segment on the other homologous chromosome (the wild-type segment is also called the WT segment, as shown in sequence 5 of the sequence table). Exemplary sequencing results are shown in Figure 4 A total of 8 F0 heterozygous mutant mice (corresponding to Figure 3 20, 21, 22, 23, 24, 25, 26 and 27 in the Figure 2A).
[0113] Sequence 4, MT fragment
[0114]
[0115] Sequence 5, WT fragment
[0116]
[0117] 5. Mouse Passaging and Line Establishment
[0118] F0 generation heterozygous mutant mice mate with wild-type mice to obtain offspring, namely F1 generation mice. There is a 50% probability that F1 generation mice are heterozygous mutant mice.
[0119] F1 generation heterozygous mutant mice can be used for experiments.
[0120] F1 generation heterozygous mutant mice can continue to be passed down.
[0121] Male F1 heterozygous mutant mice and female F1 heterozygous mutant mice mate to obtain offspring, namely F2 generation mice. There is a 25% probability that F2 generation mice are homozygous mutant mice.
[0122] Example 3: Phenotypic Identification
[0123] 1. Reproduction of heterozygous mutant mice and identification of genotype stability
[0124] The F0 generation heterozygous mutant mice obtained in Example 2 were crossed with wild-type mice to obtain F1 generation mice. Genotype identification was performed according to the method of step 4 of Example 2, and heterozygous mutant mice were selected from the F1 generation mice, namely, the F1 generation heterozygous mutant mice.
[0125] The F1 generation heterozygous mutant mice are crossed with wild-type mice to obtain F2 generation mice. Genotype identification is performed according to the method of step 4 of Example 2, and heterozygous mutant mice are selected from the F2 generation mice, namely, the F2 generation heterozygous mutant mice.
[0126] The F2 generation heterozygous mutant mice are crossed with wild-type mice to obtain F3 generation mice. Genotype identification is performed according to the method of step 4 of Example 2, and heterozygous mutant mice are selected from the F3 generation mice, namely, the F3 generation heterozygous mutant mice.
[0127] The F3 generation heterozygous mutant mice are crossed with wild-type mice to obtain F4 generation mice. Genotype identification is performed according to the method of step 4 of Example 2, and heterozygous mutant mice are selected from the F4 generation mice, namely, the F4 generation heterozygous mutant mice.
[0128] The F4 generation heterozygous mutant mice were crossed with wild-type mice to obtain F5 generation mice. Genotype identification was performed according to the method of step 4 of Example 2, and heterozygous mutant mice were selected from the F5 generation mice, namely, the F5 generation heterozygous mutant mice.
[0129] The results showed that the genotype was stably inherited.
[0130] 2. Phenotypic Identification
[0131] Test mice: F5 generation heterozygous mutant mice (13) and wild-type mice (16) from the same litter obtained in step 1. Wild-type mice from the same litter refer to mice born in the same litter as the heterozygous mutant mice, but genotyped according to the method of step 4 of Example 2, and having wild-type fragments on a pair of homologous chromosomes.
[0132] The experimental mice were fed normally.
[0133] At 4 months of age, the right ventricular systolic pressure (RVSP) and right ventricular hypertrophy index (RV / LV+S) of the test mice were measured. The right ventricular systolic pressure of heterozygous mutant mice was 22.37±1.29 mmHg, and the right ventricular hypertrophy index was 36.53%±1.70%. The right ventricular systolic pressure of wild-type mice in the same litter was 19.75±0.83 mmHg, and the right ventricular hypertrophy index was 29.49%±0.94%. The statistical results of RVSP and RV / LV+S are shown in Figure 5 .
[0134] At 4 months of age, the mice were killed, and the lungs were removed. Pathological longitudinal sections of the lungs were prepared, and HE staining and Masson staining were performed, respectively, and the pulmonary artery media thickness percentage (MWT%) was calculated. The pulmonary artery media thickness percentage of heterozygous mutant mice was 61.55% ± 2.94%. The pulmonary artery media thickness percentage of wild-type mice in the same litter was 49.42% ± 3.71%. Exemplary photos of pathological section staining and statistical results of pulmonary artery media thickness percentage are shown in Figure 6 .
[0135] The results showed that heterozygous mutant mice spontaneously developed pulmonary hypertension phenotype at 4 months of age, which was manifested by increased right ventricular systolic pressure, right ventricular hypertrophy index and pulmonary artery media thickness percentage. Therefore, heterozygous mutant mice can be used as a mouse model of pulmonary hypertension after 4 months of age.
[0136] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.
Claims
1. A method for preparing a mouse model of pulmonary hypertension, comprising the following steps: A chromosome of a wild-type mouse is subjected to targeted mutation to obtain a mutant mouse; The targeted mutation refers to: mutating the codon encoding the 182nd amino acid residue of the KCNK3 protein in the mouse genomic DNA from a codon encoding glutamate to a codon encoding glutamine.
2. A method for preparing a mouse model of pulmonary hypertension, comprising the following steps: The RNP complex is introduced into wild-type mouse fertilized eggs, which are then transferred into the uterus of surrogate mice. The offspring produced by the surrogate mice are then screened for mice with a targeted mutation on one chromosome; The RNP complex includes crRNA, tracrRNA, donor oligo and Cas9 protein; The target sequence of crRNA is: CCTTCTCCTACTACGAGCGCTGG; The donor oligo is shown as Sequence 3 in the sequence listing; The directed mutation refers to replacing the DNA segment shown in Sequence 5 of the sequence listing in the genomic DNA with the DNA segment shown in Sequence 4 of the sequence listing.
3. A method for preparing a mouse model of pulmonary hypertension, comprising the following steps: A pair of homologous chromosomes of wild-type mice were subjected to targeted mutation to obtain mutant mice; The targeted mutation refers to: mutating the codon encoding the 182nd amino acid residue of the KCNK3 protein in the mouse genomic DNA from a codon encoding glutamate to a codon encoding glutamine.
4. A method for preparing a mouse model of pulmonary hypertension, comprising the following steps: The RNP complex is introduced into wild-type mouse fertilized eggs, which are then transferred into the uterus of surrogate mice. The offspring mice produced by the surrogate mice are then screened for mice with targeted mutations in both homologous chromosomes. The RNP complex includes crRNA, tracrRNA, donor oligo and Cas9 protein; The target sequence of crRNA is: CCTTCTCCTACTACGAGCGCTGG; The donor oligo is shown as Sequence 3 in the sequence listing; The directed mutation refers to replacing the DNA segment shown in Sequence 5 of the sequence listing in the genomic DNA with the DNA segment shown in Sequence 4 of the sequence listing.
5. The method according to any one of claims 1 to 4, characterized in that: The method further comprises the following steps: culturing the mutant mice to 4 months of age, i.e., a pulmonary hypertension mouse model.
6. Use of crRNA, tracrRNA and donor oligo in preparing a kit; the kit is used to prepare a mouse model of pulmonary hypertension; The target sequence of crRNA is: CCTTCTCCTACTACGAGCGCTGG; The donor oligo is shown as Sequence 3 in the Sequence Listing.
7. Use of crRNA, tracrRNA, donor oligo and Cas9 protein in preparing a kit; the kit is used to prepare a mouse model of pulmonary hypertension; The target sequence of crRNA is: CCTTCTCCTACTACGAGCGCTGG; The donor oligo is shown as Sequence 3 in the Sequence Listing.
8. A kit comprising crRNA, tracrRNA and donor oligo; the kit is used to prepare a mouse model of pulmonary hypertension; The target sequence of crRNA is: CCTTCTCCTACTACGAGCGCTGG; The donor oligo is shown as Sequence 3 in the Sequence Listing.
9. The kit according to claim 8, characterized in that: The kit also includes a Cas9 protein.
10. The use of the pulmonary hypertension mouse model prepared by the method of any one of claims 1 to 5, wherein: (a) To study the pathogenesis of pulmonary hypertension; (b) developing drugs for pulmonary hypertension; (c) Screening of drugs for pulmonary hypertension.
